Oct 3 |
Gain Therapeutics to Participate at Upcoming Investor Conferences
|
Sep 30 |
Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson’s Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers
|
Sep 26 |
Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease
|
Sep 19 |
Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson’s Disease Models Including Two Late-Breakers at Neuroscience 2024
|
Sep 3 |
Gain Therapeutics to Participate at H.C. Wainwright 26th Annual Global Investment Conference
|
Aug 30 |
Gain Therapeutics reports positive data from Phase I Parkinson’s treatment trial
|
Aug 29 |
Gain slips after early-stage data for Parkinson’s therapy
|
Aug 29 |
Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson’s Disease
|
Aug 8 |
Gain Therapeutics GAAP EPS of -$0.42
|
Aug 8 |
Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update
|